NeuroQuest's blood-based biomarker test for early diagnosis of Alzheimer's disease exceeded U.S. Alzheimer's Association standards during recent pilot study in Australia. NeuroQuest has contracted with a major U.S. university to oversee collection and processing of 700 samples for their national clinical trial. The NeuroQuest blood test can potentially identify a pre-clinical stage of AD in a person years before the onset of noticeable symptoms, paving the way for new therapies and research.